학술논문
Safety and Efficacy Results from the Open Label Extension of a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor in Patients with Active Psoriatic Arthritis
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
23265205